PROPPR Trial Begins Enrollment
On July 31st, 2012, the Resuscitation Outcomes Consortium and the University of Texas Health Science Center at Houston received final approval to begin enrollment for the Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) study. This Phase III, twelve site clinical trial will compare the safety and efficacy of 1:1:1 transfusion ratios of plasma and platelets to red blood cells with a 1:1:2 ratio. This study will help to determine which blood transfusion combination will provide the best outcomes for trauma patients. The knowledge that can be gained from this study could impact the way in which patients who are severely bleeding are transfused, and lower the amount of otherwise preventable deaths resulting in hemorrhagic shock.
